The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

The U.S. Food and Drug Administration has also approved Bavarian's shot, but only for use in adults 18 years and older, although it granted Emergency Use Authorization for its use in adolescents ...

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

Bavarian Nordic's own pipeline is led by its universal COVID-19 booster candidate, which is due to start phase 3 later this year, and respiratory syncytial virus (RSV) candidate that should ...

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...

The MVA-BN vaccine, licensed in the United States to prevent smallpox and mpox, is well tolerated and seems effective in adolescents.

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, ...

Is Bavarian Nordic (BVNRY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Bavarian Nordic is a member of our Medical group ...